Fuel3D® to showcase how BioVolume® advances cancer research at NCRI Cancer Conference
2 November 2018
Fuel3D, a world-leading 3D technology innovator, will be showcasing for the first time in the UK, its newly updated ground-breaking BioVolume subcutaneous tumour monitoring solution at the 2018 NCRI Cancer Conference. BioVolume is the only solution in the market that combines the use of 3D imaging with thermography to monitor disease progression and response to therapy in in-vivo oncology studies.
Commenting on the launch of the new solution, George Thaw, CEO of Fuel3D said: “Following extensive evaluations with major pharmaceutical companies in Europe and the US, we’re delighted to be unveiling the latest evolution of BioVolume which sets a new standard in the quest for accurate, reproducible data and better science. By incorporating thermal imaging into our solution we’ve been able to drive significant measurement improvements which ultimately will lead to more effective trials and help speed up the discovery of vital new cancer drugs.”
Fuel3D will be hosting a breakfast briefing on ‘Why 3D imaging in preclinical trials is a step forward for cancer research’, at 8.15am-9.00am on Tuesday 6th November 2018. In their presentation, Dr Juan Delgado and Andrew Smith will share:
• The benefits and limitations of existing methods for tumour volume measurement
• How BioVolume powers better science with greater accuracy, traceability and reproducibility of data and delivers significant 3R (Refinement, Reduction and Replacement) benefits.
• Results from using 3D and thermography and how the use of AI (Artificial Intelligence) will help enable better decisions to be made at the earliest stages of drug discovery
Developed in partnership with a world-leading pharmaceutical company and wider industry, BioVolume was conceived to enable faster, smarter and more confident decisions to be made in the identification and development of new cancer therapeutics. The portable laboratory device rapidly and accurately captures and reconstructs 3D tumour surface changes, enabling the analysis of texture, colour, shape and measurements including volume.
Fuel3D will be showcasing how BioVolume can revolutionise tumour measurement at stand #43. The NCRI Cancer Conference is the UK’s largest forum showcasing the latest advances in cancer research and takes place 4-6 November 2018 in Glasgow.
For further information about Fuel3D visit www.fuel3d.com
– Ends –
Fuel3D develops innovative 3D scanning solutions for leading global brands and pioneering organisations. Our technology is re-defining solutions and inspiring better experiences across a wide range of industry sectors from medical research to security and retail. Born out of Oxford University, Fuel3D has offices in Oxford, UK and Greenville, North Carolina, US. We are at the forefront of innovation in 3D technologies with our core technology platform which rapidly and accurately captures and analyses texture, colour, shape and volume data, making it a world-class solution for organic subjects and human form applications.
For further information:
Tanya Randall, PR and Communications
Tel: +44 7887 811332